HN
Therapeutic Areas
Ryvu Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RVU120 (selinexor analog) | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | Phase 1/2 |
| RVU120 (STING agonist) | Advanced Solid Tumors | Phase 1 |
| BTX-1188 (HPK1 inhibitor) | Advanced Solid Tumors | Phase 1 |